Fresenius Kabi AG

CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3 rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor. Dr. Becker’s presentation, “Adenosine A2A Receptors as a Therapeutic Target in Autism Spectrum Disorders”, will be given next Friday. The presentation will highlight the pivotal role that Adenosine A2a receptors (A2ARs) play in the neural reward circuits involved in social interaction and communication. Research shows that A2AR antagonism consistently improves social interaction across multiple preclinical models displaying autism-like phenotypes, suggesting that drugs that target the A2AR are a very promising therapeutic target to alleviate social deficits associated with autism spectrum disorders. Marvel and Dr. Becker and Dr. Julie Le Merrer’s research team at the iBraiN institute have collaborated for the past three years to advance the scientific understanding of A2AR biology and evaluate the therapeutic potential of MB-204, Marvel's lead A2AR antagonist, in multiple preclinical models of autism (e.g., Oprm1 , Mecp2 , Shank3 – data forthcoming). "Dr. Becker is a world-class researcher whose work has been instrumental in advancing the understanding of adenosine A2A receptors in autism," said Rod Matheson, Chief Executive Officer of Marvel Biosciences. "Over the past three years, our collaboration has generated compelling preclinical data demonstrating the potential of MB-204 across multiple validated models of autism. Marvel Biosciences is proud to support the European Purine Meeting, and we hope this will raise greater awareness of this field of research in autism. " The Company is also pleased to share its recent interview with Radius Research, featuring Chief Executive Officer, Rod Matheson, and Chief Science Officer, Mark Williams. The interview shares insight into Marvel's patented lead asset, MB-204, the Company's development roadmap, upcoming milestones, and the opportunities ahead as Marvel advances toward Phase 1 clinical studies. Link to interview: About Marvel Biosciences Corp. Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson’s drug and the only adenosine A2A receptor blocker currently on the market. Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer’s disease. Marvel is also exploring MB-204’s potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments. Contact Information: Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer Email: rod@marvelbiosciences.com Dr. Mark Williams, President and Chief Science Officer Email: mark@marvelbiosciences.com Tel: 403 770 2469 Website: | Twitter/X | LinkedIn Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party. This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

PLAINFIELD, Ill., June 25, 2026 /PRNewswire/ -- Population health technology company, SNT Biotech, today announced its go-to-market solution designed to expand access to at-home cervical cancer screenings nationwide and to give women choices beyond getting care in a clinic. This announcement builds on recent U.S. Food and Drug Administration clearance of The Onclarity™ HPV Self-Collection Kit, enabled by the BD Onclarity™ HPV Assay. Federal guidelines for most insurers mean self-collected HPV screening is covered at no cost to members by 20271. Continue Reading The Onclarity™ HPV Self-Collection Kit, tested with the BD Onclarity™ HPV Assay, is the most comprehensive at-home cervical cancer screening tool available in the U.S. today. Credit: Waters Corp. Despite 4,000 women this year predicted to die from cervical cancer, it is largely preventable through routine screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers2. Yet approximately 60%3 of diagnoses occur in individuals who are unscreened or under-screened, reflecting persistent barriers to access and early detection. SNT Biotech's fully integrated population health approach solves a dilemma for health plans, managed care organizations, Federally Qualified Health Centers and provider networks that support Medicaid and commercial populations and are looking to improve cervical cancer screening rates for their hard-to-engage members. SNT Biotech's commercialization model includes an approach that helps ensure women complete and return tests to its lab to analyze. This platform helps close cervical cancer screening gaps by delivering The Onclarity™ HPV Self-Collection Kit directly to members who are overdue. At-home testing has emerged as a promising way to expand preventive care beyond traditional settings. Historically, completion and return rates for many at-home screening kits remain low, often in the single digits leaving a significant percentage of kits never returned and limiting clinical impact. SNT Biotech's platform directly reaches and educates patients throughout their screening journey - from member identification to text, email and live calls, multilingual engagement and lab processing in its CLIA and COLA-accredited facility. Results are delivered to members, primary care physicians and health plan quality teams, using real-time program dashboards. With this population health platform, SNT Biotech intends to significantly boost screening and average return rates for underserved populations. "We are thrilled to partner with Waters Corporation to advance women's health. The Onclarity™ HPV Self-Collection Kit, enabled by the BD Onclarity™ HPV Assay, which detects 14 high-risk HPV genotypes and uniquely distinguishes six individual genotypes and three strategically pooled results, offers the most comprehensive and informative HPV screening solution available in the U.S.," said Shital Daftari, founder and CEO of SNT Biotech. "We help solve a specific problem for women who need screening the most and who have the least access to it. Our screening solution combines education and infrastructure with actionable insights to address the real-world challenges of preventative care," noted Daftari. "Despite cervical cancer being preventable, a woman dies from the disease every 90 seconds. Expanding access to screening is critical, and at-home HPV self-collection removes barriers that keep people from getting screened. Extended genotyping is another significant advance, allowing clinicians to identify high-risk HPV types and enable more precise risk assessment and tailored care," said Jeff Andrews, M.D., FRCSC, Vice President of Medical Sciences, Waters Advanced Diagnostics, Waters Corporation. "We are pleased to expand access to cervical cancer screening with the Onclarity™ HPV Self-Collection Kit and approved BD Onclarity™ HPV Assay, the most comprehensive HPV screening tool available in the U.S. today, through strategic distribution partnerships." Improving screening completion rates addresses a critical driver of healthcare performance, as screening rates influence quality measures, reimbursement, and long-term cost outcomes. "Cervical cancer screening is imperative to cancer control. At-home HPV testing self-collection has the potential to change how we reach vulnerable populations who have historically had lower rates of cervical cancer screening. With this approach, we remove some of the most common barriers to screening and enhance the opportunity to detect disease earlier and improve outcomes," said Dr. Yvonne Collins, MD, gynecologic oncologist. About SNT Biotech: SNT Biotech, a minority and women-owned population health technology company, focuses on screening and advancing access to preventive care through patient-centered engagement solutions that support education, early detection, and improved health outcomes. The company partners with healthcare organizations, including health plans, to close care gaps and to ensure that diagnostic innovations translate into real-world impact. The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation ("Waters"). Becton, Dickinson and Company or one of its affiliates or subsidiaries ("BD") remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary: . Contact: Kellee Johnson for SNT Biotech, 312-751-3959, [email protected] 1 Portero, Lou. At-Home Cervical Cancer Screening Is Now Covered Under Federal Guidelines. Urban Health Today. (2026 January 29) 2 World Health Organization. (2026, March 17). Cervical Cancer. . 3 Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM et al. (2010) Cervical cancer prevention: new tools and old barriers. Cancer 116 (11): 2531-2542. SOURCE SNT Biotech 21% more press release views with Request a Demo

The Onclarity™ HPV Self-Collection Kit sets a new standard for at-home cervical cancer screening in the United States SOUTH SAN FRANCISCO, Calif., June 25, 2026 /PRNewswire/ -- Color Health, the leading nationwide virtual cancer clinic for full-spectrum cancer care, now provides the FDA-cleared Onclarity™ HPV Self-Collection Kit for at-home screening of human papillomavirus (HPV), the leading cause of cervical cancer. Color offers the swab-based kit through its ASCO-certified, oncologist-led Virtual Cancer Clinic serving employer, health plan, union, and public sector populations. The Onclarity™ HPV Self-Collection Kit, enabled by the BD Onclarity™ HPV Assay, which detects 14 high-risk HPV genotypes and uniquely distinguishes six individual genotypes and three strategically pooled results, offers the most comprehensive and informative HPV screening solution available in the U.S. today. This new screening test is part of Color's comprehensive cancer screening and early detection program. Through its Virtual Cancer Clinic, Color provides additional at-home tests for other guideline-recommended cancer screenings, a high quality lower cost imaging screening network, and genetic risk testing. Color Medical's clinical team orders and follows up on every screening test, ensuring complete clinical management and accountability for the screening process. Color's program has demonstrated a 77% increase in screening adherence, including 100% clinical follow up for every abnormal result. The approach has been proven to reduce costs of care delivery relative to traditional network models and reduces time for patients to go from abnormal result to a cancer diagnosis by 66%. HPV is a common sexually transmitted infection responsible for over 90% of cervical cancer cases. Yet one in four eligible women are not up to date with cervical cancer screening, and 60% of cervical cancers occur in people who haven't been screened in the last five years or ever. "Cervical cancer is one of the most preventable cancers yet too many people remain unscreened due to barriers like access, time, and discomfort with in-clinic exams," said Dany Matar, Chief Operating Officer, Color Health. "Screening is a process, not a one-time test, and Color is unique in integrating this process into an expert clinical model that ensures not only that this screening is more accessible for patients, but that every screening follow-up happens quickly. Providing this new option through Color's Virtual Cancer Clinic broadens access to convenient high-quality testing for our patients." Self-collection makes screening more accessible to patients who may find traditional pelvic exams uncomfortable or who face other barriers to care. Further, the Onclarity™ HPV Self-Collection Kit enabled by the Onclarity™ HPV Assay is the only FDA-approved HPV test with both extended genotyping† of individual results beyond HPV 16, 18, 45 and the option of self-collection.* "Despite cervical cancer being preventable, a woman dies from the disease every 90 seconds. Expanding access to screening is critical, and at-home HPV self-collection removes barriers that keep people from getting screened. Extended genotyping is another significant advance, allowing clinicians to identify high-risk HPV types and enable more precise risk assessment and tailored care." said Jeff Andrews, M.D., FRCSC, Vice President of Medical Sciences, Waters Advanced Diagnostics, Waters Corporation. "We are pleased to expand access to cervical cancer screening with the Onclarity™ HPV Self-Collection Kit and approved BD Onclarity™ HPV Assay, the most comprehensive HPV screening tool available in the U.S. today, through strategic distribution partnerships." About Color Health Color's Virtual Cancer Clinic, powered by Color Medical's 50-state, oncologist-led medical group, has transformed cancer care for employers, health plans, unions and the public sector. Combining technology and AI with a fully integrated medical group, Color's ASCO-certified virtual clinic broadens access to best-in-class care, and lowers costs by avoiding late-stage diagnoses. Color identifies high-risk members, detects cancer earlier through guidelines–based screening, improves outcomes for patients in active treatment, and fully supports the unique needs of cancer survivors. Connect with Color on LinkedIn, X, and Color.com. The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation ("Waters"). Becton, Dickinson and Company or one of its affiliates or subsidiaries ("BD") remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary: . *Self-collected vaginal specimens can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained. †There are currently two FDA-approved HPV tests with extended genotyping with different configurations. The BD Onclarity™ HPV Assay individually identifies 6 high-risk HPV genotypes and strategically groups 3 results for 8 moderate risk HPV genotypes Media Contact: Color Health Andy Kill [email protected] SOURCE Color Health 21% more press release views with Request a Demo